References
Mitchell TJ, John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology. 2005;114:301–12.
Waldmann TA. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. Mol Cell Endocrinol. 2017;451:66–70.
Sharma A, Oishi N, Boddicker RL, Hu G, Benson HK, Ketterling RP, et al. Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood. 2018;131:2262–6.
Jaffe ES, Chott A, Ott G, Chan JKC,GB, Tan SY, et al. Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours. Revised 4th ed. Lyon: International Agency for Research on Cancer; 2017. pp. 379–80.
Vega F, Medeiros LJ. Chromosomal translocations involved in non-Hodgkin lymphomas. Arch Pathol Lab Med. 2003;127:1148–60.
Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000;95:2076–83.
Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268–77.
Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309–12.
Yao L, Wen L, Wang N, Liu T, Xu Y, Ruan C, et al. Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA. Blood. 2018;131:935–9.
Perry AM, Warnke RA, Hu Q, Gaulard P, Copie-Bergman C, Alkan S, et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood. 2013;122:3599–606.
Hobbs GS, Rozelle S, Mullally A. The development and use of Janus kinase 2 inhibitors for the treatment of myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2017;31:613–26.
Ehrentraut S, Nagel S, Scherr ME, Schneider B, Quentmeier H, Geffers R, et al. t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5. PLoS ONE. 2013;8:e53767.
Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024.
Margolskee E, Jobanputra V, Lewis SK, Alobeid B, Green PH, Bhagat G. Indolent small intestinal CD4+ T-cell lymphoma is a distinct entity with unique biologic and clinical features. PLoS ONE. 2013;8:e68343.
Gorantla S, KS B, AL I, N vB, C P, Duyster J. Ruxolitinib mediated paradox JAK2 hyperphosphorylation is due to the protection of activation loop phosphotyrosines from phosphatases. Blood. 2013;122:2847.
Acknowledgements
This work was supported by Award Numbers R01 CA177734 (ALF), P30 CA15083 (Mayo Clinic Cancer Center), and P50 CA97274 (University of Iowa/Mayo Clinic Lymphoma SPORE) from the National Cancer Institute; Grant number 6574-19 from the Leukemia & Lymphoma Society; the Department of Laboratory Medicine and Pathology, Mayo Clinic; the Clinomics Program of the Center for Individualized Medicine, Mayo Clinic; and the Predolin Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
GSN has consulted for Celgene, MorphoSys, Bayer, AbbVie, Janssen, Selvita, Karyopharm Therapeutics, and Soreno, and has received research support from Curis, Roche, Celgene, MorphoSys, and NanoString. ALF has received research support from Seattle Genetics. The remaining authors have no competing financial interests to declare.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hu, G., Phillips, J.L., Dasari, S. et al. Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract. Leukemia 34, 1467–1471 (2020). https://doi.org/10.1038/s41375-019-0678-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-019-0678-3
- Springer Nature Limited